[Therapy of dementing diseases: value of calcium antagonists]
- PMID: 8282287
[Therapy of dementing diseases: value of calcium antagonists]
Abstract
The possibilities and limitations of treatment of dementia with nootropic agents are discussed. Particular attention is directed to the calcium antagonist, nimodipine, with its demonstrably excellent efficacy. Treatment with nootropic agents should be initiated after meticulous establishment of the diagnosis of dementia and continued over the long-term, if their effectiveness is clinically manifest.
Similar articles
-
[Effectiveness and tolerance of nimodipine in long-term treatment of patients with organic brain disorders].Z Arztl Fortbild (Jena). 1992 May 11;86(9):451-6. Z Arztl Fortbild (Jena). 1992. PMID: 1604901 German. No abstract available.
-
Nimodipine prior to alcohol withdrawal prevents memory deficits during the abstinence phase.Neuroscience. 2008 Nov 19;157(2):376-84. doi: 10.1016/j.neuroscience.2008.09.010. Epub 2008 Sep 11. Neuroscience. 2008. PMID: 18835336
-
Nimodipine plus zidovudine versus zidovudine alone in the treatment of HIV-1-associated cognitive deficits.AIDS. 1997 Oct;11(12):1520-1. AIDS. 1997. PMID: 9342076 Clinical Trial. No abstract available.
-
[Altered calcium homeostasis in brain aging and senile dementia, new approach to treat Alzheimer's disease].Yao Xue Xue Bao. 1993;28(9):641-6. Yao Xue Xue Bao. 1993. PMID: 8010007 Review. Chinese. No abstract available.
-
[Treatment with nootropic drugs].Fortschr Med. 1990 Mar 30;108(9):178-80. Fortschr Med. 1990. PMID: 2187782 Review. German.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical